This trial is part the myeloMATCH precision medicine initiative for people with myeloid malignancies. The myeloMATCH Screening and Reassessment Protocol (MSRP) is led by the SWOG Cancer Research Network and treatment trials are led by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG. The entire initiative is sponsored by the National Cancer Institute through its National Clinical Trials Network.